NCT00502034View on ClinicalTrials.gov

Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma.

PHASE3CompletedINTERVENTIONAL
Enrollment

310

Participants

Timeline

Start Date

July 31, 1994

Primary Completion Date

April 30, 2007

Study Completion Date

June 30, 2012

Conditions
Carcinoma, Renal Cell
Interventions
DRUG

Interferon Alfa-2a

Interferon Alfa-2a in combination with Interleukin

DRUG

Interleukin-2

Interferon Alfa-2a in combination with Interleukin

Trial Locations (8)

24128

Ospedali Riuniti di Bergamo, Bergamo

26100

Istituti Ospitalieri di Cremona, Cremona

27100

Pavia University Hospital, Pavia

29100

"Ospedale Guglielmo da Saliceto", Piacenza

41012

Carpi Hospital, Carpi

41100

Modena University Hospital, Modena

42100

Arcispedale Santa Maria Nuova, Reggio Emilia

43100

Parma University Hospital, Parma

All Listed Sponsors
lead

Gruppo Oncologico Italiano di Ricerca Clinica

OTHER

NCT00502034 - Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma. | Biotech Hunter | Biotech Hunter